Vsling for Heart Failure: A first look at repair of the ventricle

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter, open-label study evaluates the feasibility, initial safety, and performance of the Vsling device in patients with heart failure and reduced ejection fraction due to ventricular dilation. Eligible participants have specific LV dimensions, FMR limitations, and NYHA class symptoms. The primary aim is to observe procedural practicality and early safety signals in a real-world setting. Enrollment is at least in a single international center, with careful exclusion of patients with certain prior surgeries or device implants. The lead sponsor is Cardiac Success, with the study site at John Paul II Hospital in Krakow.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age≥ 18 and \< 85 years
2. Left ventricular end diastolic diameter is greater than or equal to 55mm
3. Ejection fraction ≥20% and ≤40%
4. FMR grade ≤ 2+ (≤ mild FMR) as defined by the guidelines of the American society of echocardiography (via a transthoracic or transesophageal echo)
5. End-systolic Interpapillary muscle distance ≥ 20mm
6. NYHA class II-IVa
7. Cardiomyopathy of ischemic or non-ischemic origins
8. Understands the nature of the study and procedure and able to provide written informed consent

Exclusion Criteria:

1. Any evidence of structural (chordal or leaflet) mitral lesions
2. Ventricular tachycardia or ventricular fibrillation within 6 months prior to inclusion in this study
3. Prior mitral valve repair or replacement
4. ICD/CRT/cardiac pacemaker leads implanted within 3 months prior to inclusion in this study
5. Clinical signs of cardiogenic shock within 30 days prior to inclusion in this study
6. Anatomy that, in the opinion of the interventionalist, prevents safe passage of the Vsling™ catheter(s).
7. Severe aortic stenosis
8. Severe, massive, or torrential tricuspid regurgitation requiring surgical or transcatheter repair
9. Known fixed pulmonary hypertension with PA systolic pressure \>70 mmHg not responsive to vasodilator therapy
10. ST segment elevation myocardial infarction within 30 days prior to inclusion in this study
11. Congenital heart disease (except PFO, PDA or ASD)
12. Heart Failure due to confirmed amyloid or other restrictive cardiomyopathies
13. Chronic renal insufficiency defined by Creatinine ≥ 3.0 mg/dL or chronic renal replacement therapy
14. Any therapeutic invasive cardiac procedure within 30 days prior to inclusion in the study
15. Any cardiac surgery, within 3 months prior to inclusion in the study
16. Cerebrovascular Accident (CVA) within 90 days prior to inclusion in this study
17. Thrombocytopenia (Platelet count\< 100,000/mm3) or thrombocytosis (Platelet count \> 750,000/mm3)
18. Body temperature \>38°C within 3 days prior to index procedure
19. Bleeding disorders or hypercoagulable state
20. Active peptic ulcer or active gastrointestinal (GI) bleeding within 90 days of the scheduled implant
21. Contraindication to anticoagulants or antiplatelet agents
22. Known allergy to stainless steel, nickel, titanium or contrast agents that cannot be adequately pre-medicated
23. Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically
24. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
25. Co-morbid condition(s) that, in the opinion of the Investigator, limit life expectancy to \< 12 months
26. Co-morbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
27. Pregnancy

Where it's running

• John Paull II Hospital
  Krakow, Poland Recruiting

Study contacts

• Study coordinator: Iris Yadin-Herling
• Email: iris.yh@cardiacsuccess.com
• Phone: 972546633352

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guideline Adherence in HFrEF: See If Mirror Information Helps Doctors and Patients Follow GDMT

  This study tests whether showing doctors, or both doctors and patients, mirror information about how well guideline-directed medical therapy is being used in heart failure with reduced ejection fraction.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07702760

• Eccentric Muscle Training in Cardiac Rehab for Heart Failure with Reduced Ejection Fraction

  This study tests eccentric overload and eccentric cycling as part of a cardiac rehabilitation program for people with HFrEF to see if they build more muscle strength and mass than traditional training.

  Recruiting University Hospital, Antwerp · Edegem · NCT07636343

• Impact of Barostim on heart function in adults with reduced ejection fraction

  This trial tests whether implanting and adjusting the Barostim device can improve heart function and exercise ability in adults with HFrEF already taking maximal guideline-directed therapies.

  Recruiting Columbia University · San Francisco, California and 6 other locations · NCT07335510

• Predicting who improves after phase II cardiac rehabilitation for reduced ejection fraction

  This project will test whether blood microRNA patterns together with non-invasive exercise measurements can predict which people with reduced ejection fraction heart failure will improve their peak oxygen uptake after a phase II cardiac rehab program.

  Recruiting Centre Hospitalier de Corbie · Corbie · NCT07164911

• Swedish heart and kidney failure pilot

  This trial will test whether the drug eplerenone is safe and feasible for people with heart failure with reduced ejection fraction who also have severe chronic kidney disease.

  Recruiting Phase 2 Karolinska Institutet · Stockholm · NCT07029503

• Exploring heart failure and diabetes interactions

  This study looks at how heart failure and diabetes affect the body differently by testing 600 people with various combinations of these conditions.

  Recruiting University of Leeds · Leeds, West Yorkshire · NCT06774014

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.